Skip to main content

Table 1 Frequency of FH-autoantibodies and CFHR1 deficiency in patients compared to healthy controls.

From: Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome

Total number of patients and controls FH-autoantibody positive individuals FH-autoantibody negative individuals Odds Ratio for anti-FH positivity in CFHR1 deficiency
   % No. CFHR1 deficiency
No. (%)
No. CFHR1 deficiency
No. (%)
OR 95% CI P-value
LA+
Sweden
64 9.4 6 5 (83.3) 58 1 (1.7) 285 15.4 to 5,280 <0.0001
Controls
Sweden
64 6.3 4 1 (25.0) 60 1 (1.7) 20 1.0 to 397 1.12
SLE
Low SLEDAI, Sweden
30 0.0 0 0 (0.0) 30 1 (3.3) n.a1   
Controls
Sweden
30 0.0 0 0 (0.0) 30 0 (0.0) n.a.   
SLE
High SLEDAI, Sweden
30 13.3 4 0 (0.0) 26 1 (3.8) 2.0 0.066 to 54.1 1
Controls
Sweden
30 10.0 3 0 (0.0) 27 1 (3.7) 6.3 0.17 to 231 1
RA
Sweden
97 16.5 16 2 (12.5) 81 5 (6.2) 2.0 0.38 to12.3 0.3
Controls
Sweden
97 2.1 2 0(0.0) 95 1(1.1) 12.3 0.44 to 384 1
RA
The Netherlands
217 9.2 20 0 (0.0) 197 7 (3.6) n.a.   
Controls
The Netherlands
161 3.1 5 0 (0.0) 156 13 (8.3) n.a.   
aHUS
Germany
103 11.7 12 3 (25.0) 91 4 (4.4) 6.45 1.25 to 33.05 0.04
Controls
Germany
20 5.0 1 0 (0.0) 19 0 (0.0) n.a.   
  1. 1n.a., not applicable due to 0% frequency